日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / China-US

New medicine for prostate cancer available in China

chinadaily.com.cn | Updated: 2019-11-28 16:49
Share
Share - WeChat

New medicine to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC) is available in China to save those at high risk of developing metastases.

The Xian Janssen Pharmaceutical Ltd announced on Wednesday that ERLEADA (apalutamide) was put on the market in China after being granted by the China National Medical Products Administration (NMPA) in September, recognizing the urgent unmet need for patients with nmCRPC who currently have few treatment options.

ERLEADA is an androgen receptor inhibitor that works by preventing androgen from binding to the androgen receptor. It has been shown to delay the time to distant metastasis. Treatment with ERLEADA has also shown to result in the control of Prostate-Specific Antigen (PSA) levels, which is an important indicator during the early treatment and prognosis of patients with prostate cancer.

According to Professor Zhou Liqun, Head of Urology Department in Peking University First Hospital, the five year survival rate for advanced mCRPC patients is only 3% before the new method of endocrine treatment. "This rate increased to only 30% even with new treatment. So it is urgent to postpone progression and to maintain quality of life for patients living with nmCRPC and the approval of ERLEADA presents a new treatment option that can potentially addres this treatment.

The incidence rate of prostate cancer in China has increased and become one of the top five of the most common male cancers in the country over the past decade. The androgen-deprivation therapy (ADT) is the current standard of care for nmCRPC. However, if after initial sustained treatment with ADT, the cancer cells continue to progress without distant metastasis, patients will enter a stage called nmCRPC. Without interventions, 90% of patients with nmCRPC will eventually develop bone metastases, which can lead to pain, fractures and spinal cord compression.

According to data from a clinical study, ERLEADA reduced the risk of advanced metastasis or death by 72% and increased median metastasis-free survival by over two years among patients with nmCRPC who are undergoing continuous ADT treatment.

Professor Wang Jianye, Dean of Beijing Hospital and Director of National Center of Gerontology, said "In recent years, urology and oncology doctors are working on new NM-CRPC treatment and medicine. ERLEADA optimizes the standard NM-CRPC treatment in China and provides quality time for patients and their families."

"As one of the leading pharmaceutical companies in China, Xian Janssen has been dedicated to helping patients with prostate cancer in China. We recognize the varied needs of patients across all stages of prostate cancer, which require collaborative efforts from government, society and the healthcare industry to address. To help patients with prostate cancer receive better treatment, we are committed to exploring the full potential of our solutions in addressing unmet treatment needs across all stages of disease progression," said Asgar Rangoonwala, President of Xian Janssen.

ERLEADA is now available in major Chinese cities including Beijing, Shanghai, Guangzhou and Tianjin. Xian Janssen is supporting the China Primary Healthcare Foundation to launch a Patient Access Program that helps low-income patients in China access treatment with ERLEADA.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 婷婷午夜| 精品国产中文字幕 | 日本精品一区二区三区四区 | 在线观看黄色小视频 | 国产成人精品综合 | 中文字幕第一页在线 | 小明看看在线视频 | 国产欧美一区二区三区另类精品 | 日本网站在线播放 | 狠狠草视频 | 国内精品久久久久久中文字幕 | 欧美精品一区三区 | 成人欧美一区二区三区在线播放 | 欧美成年视频 | 日日日日日 | 久久最新精品 | 精品久久久久久久久久久 | 国产一区二区三区在线 | 免费黄色在线观看 | 欧美激情综合色综合啪啪五月 | 亚洲一区二区三区免费在线观看 | www.妞干网.com| 一区二区三区在线播放 | 国产91网| 国产成人视屏 | 一区二区三区欧美精品 | 日韩欧美在线播放 | 九九99九九在线精品视频 | 成人免费久久精品国产片久久影院 | 欧美另类视频在线 | 91青青国产在线观看免费 | 色天天久久 | 日日碰狠狠添天天爽五月婷 | 免费又粗又硬进去好爽A片视频 | 亚洲成人在线免费视频 | 亚洲精品中文字幕在线观看 | 亚洲国产视频在线观看 | 青青在线香蕉精品视频免费看 | 国产精品自线在线播放 | 人妻熟女久久久久久久 | 一区中文 |